SCHEMBL10242931

SCHEMBL10242931

CCNC(=O)Cc1cccc(-c2ccco2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT6 Q96LA8 1/20 0.56
KEAP1 Q14145 1/20 0.48
ALDH1A1 P00352 5/20 0.46
POLB P06746 3/20 0.46
HPGD P15428 2/20 0.46
HIF1A Q16665 2/20 0.46
PSMB5 P28074 3/20 0.45
SMN1; SMN2 Q16637 4/20 0.43
CTSS P25774 1/20 0.43
CTSK P43235 1/20 0.43
KDM4E B2RXH2 4/20 0.42
MAPT P10636 3/20 0.41
CYP3A4 P08684 2/20 0.41
CYP2C9 P11712 2/20 0.41
CYP2C19 P33261 2/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
TAAR1 Q96RJ0 2/20 0.41
ADORA3 P0DMS8 1/20 0.41
HSD17B10 Q99714 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10242915 0.90 PRMT6 (0.53) PRMT6KEAP1ALDH1A1POLBHPGD
SCHEMBL10242902 0.87 PRMT6 (0.51) PRMT6KEAP1ALDH1A1POLBHPGD
SCHEMBL10242910 0.87 PRMT6 (0.53) PRMT6KEAP1ALDH1A1POLBHPGD
SCHEMBL12250924 0.86 PRMT6 (0.52) PRMT6KEAP1ALDH1A1POLBHPGD
SCHEMBL5662919 0.81 PRMT6 (0.58) PRMT6KEAP1ALDH1A1POLBHPGD
SCHEMBL10243178 0.81 PRMT6 (0.52) PRMT6KEAP1ALDH1A1POLBHPGD
SCHEMBL5664152 0.80 KEAP1 (0.59) PRMT6KEAP1ALDH1A1POLBHPGD
SCHEMBL10242930 0.79 PRMT6 (0.60) PRMT6KEAP1ALDH1A1POLBHPGD
SCHEMBL10242941 0.78 KEAP1 (0.61) PRMT6KEAP1ALDH1A1POLBHPGD
SCHEMBL12303899 0.77 PRMT6 (0.51) PRMT6KEAP1ALDH1A1HPGDPSMB5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 PRMT6 1751/4885KEAP1 3364/4885ALDH1A1 1939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.